Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Trifluoroacetic acid-13C sodium | 286425-32-9 | 98.0% | 137.00 g/mol | C13CF3NaO2 | 1mg
Trifluoroacetic acid-13C sodium is the 13C labeled isotope of Trifluoroacetic acid-13C (sodium) (HY-W754811)[1]
Medchemexpress LLC Α-MSH (TFA) | 171869-93-5 | 98.5% | 25 MG
α-MSH TFA (α-Melanocyte-Stimulating Hormone TFA) is an endogenous neuropeptide that acts as a melanocortin receptor 4 (MC4R) agonist. It exhibits anti-inflammatory and antipyretic activities, being a post-translational derivative of pro-opiomelanocortin (POMC).
- Modulates CNS inflammation by acting directly on melanocortin receptors in glial cells.
- Modulates NFκB activation.
- Inhibits translocation of transcription factor κB to the nucleus.
- Effectively modulates inflammatory reactions when given systemically.
Sigma Aldrich Fine Chemicals Biosciences Trifluoroacetic acid 99 fo100G
TRIFLUOROACETIC Trifluoroacetic acid 99 fo100G
Medchemexpress LLC Ecallantide (DX-88) trifluoroacetate | 00-00-0 | 7053.81 g/mol (free base) | C305H442N88O91S8 · xC2HF3O2 | 5 MG
Ecallantide TFA is a recombinant plasma kallikrein inhibitor supplied as the trifluoroacetate salt for research use. It inhibits kallikrein-mediated formation of bradykinin and is used in laboratory studies of angioedema and bradykinin-related pathways. Provided in defined small-scale packages for analytical and preclinical research; not for human use.
- Specific recombinant plasma kallikrein inhibitor.
- Trifluoroacetate salt formulation for stability and handling.
- Available in small, defined package sizes suitable for research.
- Characterized molecular weight and molecular formula provided.
- Intended for research use only; not for clinical or human use.
- Applicable to studies of bradykinin-mediated signaling and angioedema models.
Medchemexpress LLC Ecallantide TFA | 9007-83-4 | 99.54% | 7053.81 | 50 MG
Ecallantide TFA is a specific recombinant plasma kallikrein inhibitor that works by inhibiting the production of bradykinin, thereby offering a potential treatment for acute attacks of angioedema.
- Specific recombinant plasma kallikrein inhibitor
- Inhibits the production of bradykinin
- May be used to prevent acute attacks of angioedema
Medchemexpress LLC PZ703b trifluoroacetate | 98.6% | 1714.46 g/mol | C82H103ClF6N10O13S4 | 5 MG
PZ703b TFA is a Bcl-xL-targeting PROTAC degrader provided for laboratory research use. It induces rapid BCL-XL degradation, triggers caspase-3-mediated apoptosis, and inhibits cancer cell proliferation in vitro, including activity in bladder cancer models and hematologic cell lines. Supplied as a trifluoroacetate salt, it is intended for biochemical and cell-based studies only.
- Bcl-xL PROTAC degrader that promotes targeted protein degradation.
- Induces caspase-3-mediated apoptosis in susceptible cell lines.
- Inhibits cell proliferation and can act synergistically with other small-molecule inhibitors in vitro.
- Demonstrated low-nanomolar cellular potency in selected hematologic cell lines.
- High purity (>98%) suitable for biochemical and cell-based assays.
- Available in small milligram pack sizes for research use only.
Medchemexpress LLC Gmprga Tfa | 98.1% | 5 MG
GMPRGA TFA is the trifluoroacetic acid (TFA) salt form of GMPRGA. It is known to recognize spAimR in the bacterial cytosol, a process that induces lysogeny.
- TFA salt form
- Recognizes spAimR in bacterial cytosol
- Induces lysogeny
- Functions as an inhibitor
- Part of bacterial lysis-lysogeny studies
- Classified as an antimicrobial peptide
Medchemexpress LLC Mal-PEG4-C2-NH2 TFA | 2512227-13-1 | 98.6% | 430.37 | 500 MG
Mal-PEG4-C2-NH2 TFA is a PEG-based PROTAC linker used in the synthesis of PROTACs. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
- PEG-based PROTAC linker
- Used in the synthesis of PROTACs
- Facilitates selective degradation of target proteins
Medchemexpress LLC Tcmcb07 tfa | 1456699-27-6 | 99.69% | 1344.5 g/mol | 1 MG
TCMCB07 TFA is a cyclic nonapeptide, recognized as an orally active and brain-penetrant antagonist of the melanocortin receptor 4 (MC4R). It is noted for its important role in cachexia and exhibits potential transport capabilities.
- Cyclic nonapeptide MC4R antagonist
- Orally active and brain-penetrant
- Important for cachexia research
- Exhibits potential transport capabilities
- Known to stimulate food intake and weight gain in rats
Waters Corp Proteomics Training Standards, Kit
Waters Corporation Proteomics Training Standards, Kit
Medchemexpress LLC Vm24-toxin (Vaejovis mexicanus peptide 24) | 1373890-79-9 | 3863.59 | 1 MG
Vm24-toxin (Vaejovis mexicanus peptide 24) is a 36-residue peptide that acts as a potent and selective Kv1.3 blocker with a Kd of approximately 3 pM in lymphocytes. It exhibits over 1500-fold higher affinity for Kv1.3 compared to other assayed potassium channels. Vm24-toxin possesses a distorted cystine-stabilized α/β motif, comprising a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. This peptide can attenuate the CD4+ effector memory T cell response to T cell receptor (TCR) stimulation.
- Potent and selective Kv1.3 blocker
- High affinity for Kv1.3 over other potassium channels (>1500-fold)
- Attenuates CD4+ effector memory T cell response to T cell receptor (TCR) stimulation
Medchemexpress LLC Dendrotoxin-I (TFA) | 99.9% | 7149.24 | 5 MG
Dendrotoxin-I (DTX-I) TFA is a potent K+ channel blocker with IC50s of 0.13-50 nM for voltage-gated potassium channel subunits KV1.1, KV1.2, and KV1.6. This neurotoxin has potential for cancer research.
- Potent K+ channel blocker.
- Targets voltage-gated potassium channel subunits KV1.1, KV1.2, and KV1.6.
- Potential for cancer research.
- Shows significant tumor growth inhibition effect in nude mice with MCF-7 cells when combined with hyperthermia (at 5 mg/kg IV).
Medchemexpress LLC Saralasin TFA | 34273-10-4 | 99.18% | 1026.07 | 25 MG
Saralasin TFA, an octapeptide analog of angiotensin II, functions as a competitive angiotensin II receptor antagonist and exhibits partial agonist activity. It is utilized in the research of renovascular hypertension and renin-dependent (angiotensinogenic) hypertension.
- Competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM.
- Exhibits partial agonist activity.
- Inhibits cell growth in 3T3 and SV3T3 cells.
- Restores potassium currents in myocytes.
- Inhibits binding of FITC-Ang II to rat liver membrane preparation.
- Reduces ovulation rate and prostaglandin levels in vitro.
- Ameliorates oxidative stress and tissue injury in cerulein-induced pancreatitis in rats.
- Increases serum renin activity in normal, conscious rats.
Medchemexpress LLC LAGIPRA peptide (TFA) | 98.2% | 5756.50 (free base) | 5 MG
LAGIPRA peptide TFA is a long-acting GIP1R agonist that enhances insulin sensitivity by augmenting glucose disposal. It also reduces branched-chain amino acids (BCAAs) and ketoacids, making it a potential subject for research into type 2 diabetes.
- Long-acting GIP1R agonist
- Enhances insulin sensitivity by augmenting glucose disposal
- Reduces branched-chain amino acids (BCAAs) and ketoacids
- Potential for research into type 2 diabetes